One hundred twenty-seven patients with advanced ACC treated with mitotane...67% of patients with low tumor burden and mitotane initiation ≥360 days after primary diagnosis experienced a clinical benefit (stable disease >180 days).Patients who achieved mitotane levels >14 mg/L had significantly longer OS (HR 0.42; P = 0.003).